Persistent hepatocyte secretory failure in lopinavir/ritonavir related to drug-induced liver injury: a case report

Persistent hepatocyte secretory failure in lopinavir/ritonavir related to drug-induced liver injury: a case report

Lopinavir/ritonavir, an anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) drug, may be associated with the development of liver injury. In this paper, we reported an elderly female patient with drug-induced liver injury secondary to lopinavir/ritonavir, which was evaluated for their...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yue Sun, Ran Wang, Cai'e Wang, Xiaodong Shao, Xiaojie Zheng, Hui Li, Yingkai Chi, Baocheng Deng, Yiling Li, Shenghao Jin, Xingshun Qi
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-02-01
Series:	Frontiers in Medicine
Subjects:	case report drug-induced liver injury persistent hepatocyte secretion failure lopinavir/ritonavir updated RUCAM
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2025.1492002/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Bilateral pedal edema in an HIV patient: Lopinavir/Ritonavir-containing treatment regimen as a potential cause?
by: Hasan M. Shihab, et al.
Published: (2009-06-01)

Severe COVID-19 infection in a kidney transplant recipient treated with lopinavir/ritonavir, hydroxychloroquine and dexamethasone
by: Satriyo Dwi Suryantoro, et al.
Published: (2021-09-01)

Lopinavir/ritonavir as part of schemes of HAARt in HIV-positive pregnant women and women of reproductive age: the dynamics of clinical and immunological and virological indicators
by: A. B. Konkova-Reidman, et al.
Published: (2015-04-01)

Cartilage-protective effects of lopinavir/ritonavir: in vitro and in silico exploration of the HIF-1α/SOX9/IL-1β pathway
by: Hanefi Ozbek, et al.
Published: (2025-07-01)

IMPROVING ANTIRETROVIRAL THERAPY IN CHILDREN WITH HIV INFECTION
by: V. B. Denisenko, et al.
Published: (2018-07-01)

Drug-Induced Autoimmune Hepatitis: Robust Causality Assessment Using Two Different Validated and Scoring Diagnostic Algorithms
by: Rolf Teschke, et al.
Published: (2025-06-01)

Experience in Using Antiviral Agents for the Treatment of Novel Coronavirus Infection (COVID-19) in Kyrgyzstan
by: A. A. Zurdinova, et al.
Published: (2021-12-01)

Examining efficacy and safety of ethyl acetate extract from Allium hirtifolium as complementary therapy in COVID-19: A randomized, multicenter, controlled clinical trial
by: Mansour Amin, et al.
Published: (2024-11-01)

Affecting factors to effectiveness of starting therapy in children with hiv infection
by: V. B. Denisenko, et al.
Published: (2015-11-01)

Pharmacovigilance of Drug–Drug Interactions with Nirmatrelvir/Ritonavir
by: Victoria Hendrick, et al.
Published: (2024-10-01)

Structural multiplicity in a solvated hydrate of the antiretroviral protease inhibitor Lopinavir
by: Tebogo M. L. Mokoto, et al.
Published: (2024-11-01)

Experience with Empirical Treatment of Severe Acute Respiratory Syndrome Due to Coronavirus, Genotype IV
by: V. N. Shchukina, et al.
Published: (2020-05-01)

DYNAMICS OF CLINICAL LABORATORY PARAMETER IN HIV-INFECTED CHILDREN UNDERGOING DIFFERENT PATTERNS OF INITIAL HIGHLY ACTIVE ANTIRETROVIRAL THERAPY: RANDOMIZED CONTROLLED TRIAL
by: V. B. Denisenko, et al.
Published: (2016-02-01)

Chemical and Toxicological Analysis of Antiretroviral Drugs
by: T. N. Komarov, et al.
Published: (2019-11-01)

Real-world effectiveness of simnotrelvir-ritonavir versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 during the omicron wave in China: a retrospective cohort study
by: Chuntao Li, et al.
Published: (2025-07-01)

Potential drug interaction after withdrawal of nirmatrelvir-ritonavir in hospitalized patients with COVID-19 infection
by: Yun Han, et al.
Published: (2025-05-01)

Influencing factors and mechanism of hepatocyte regeneration
by: Xiaoyi Zhang, et al.
Published: (2025-04-01)

Application of nirmatrelvir/ritonavir for the treatment of severe COVID-19 in a 3-year-old child
by: Xia Wang, et al.
Published: (2024-11-01)

Effectiveness and safety of azvudine versus nirmatrelvir/ritonavir in hospitalized patients with COVID-19
by: Jin Yang, et al.
Published: (2025-05-01)

Development and Validation of Atazanavir and Ritonavir Determination in Human Plasma by HPLC-MS Method
by: T. N. Komarov, et al.
Published: (2020-02-01)

Methimazole‐induced cholestasis initially obscured by an incidental finding of a large periampullary diverticulum: A case report with reference to the updated RUCAM of 2016
by: Salomon Chamay, et al.
Published: (2025-02-01)

Efficacy of Nirmatrelvir tablet/Ritonavir tablet in patients infected with COVID-19 aged 90 years and older
by: WEI Xueman, et al.
Published: (2025-05-01)

Short- and long-term comparative effectiveness of nirmatrelvir/ritonavir and molnupiravir in asthma patients: a cohort study
by: Guozhang Lin, et al.
Published: (2025-02-01)

Exploring the therapeutic mechanism of itraconazole combined with ritonavir on Candida albicans infection through network pharmacology and molecular docking
by: Yiyang Feng, et al.
Published: (2025-07-01)

Factors influencing Nirmatrelvir/Ritonavir concentration in patients with COVID-19
by: Ping Xu, et al.
Published: (2024-12-01)

Association between nirmatrelvir/ritonavir treatment and antibiotic prescribing in the outpatient setting among patients with COVID-19
by: Aisling R. Caffrey, et al.
Published: (2025-04-01)

Characterizing morphological heterogeneity in porcine hepatocytes
by: KIRPAL SINGH, et al.
Published: (2025-02-01)

Simultaneous Determination of Nirmatrelvir and Ritonavir in Human Plasma by HPLC-MS/MS
by: T. N. Komarov, et al.
Published: (2023-05-01)

Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
by: Samuel Theodorus Sutanto, et al.
Published: (2023-01-01)

Risk Factors for Seeking Medical Care Following Nirmatrelvir-Ritonavir (Paxlovid) Treatment for COVID-19: “Symptom Rebound”
by: Ashish Bhargava, et al.
Published: (2025-05-01)

Toxicity for warfarine switching from lopinavir/ritonavir to dolutegravir
by: Ana Pelufo-Pellicer, et al.
Published: (2017-03-01)

Real-world effectiveness and economic analysis of nirmatrelvir/ritonavir, remdesivir, and molnupiravir for treatment of COVID-19 among ambulatory patients in Thailand
by: Sirapat Korwiwattanakan, et al.
Published: (2025-08-01)

MODERN DIRECTED ANTIVIRAL COVID-19 THERAPY: RESULTS OF MULTICENTER CLINICAL EFFECTIVENESS AND SAFETY STUDY OF FIXED NIRMATRELVIR+RITONAVIR COMBINATION
by: L. A. Balykova, et al.
Published: (2022-10-01)

Immunology Highlights of Four Major Idiosyncratic DILI Subtypes Verified by the RUCAM: A New Evidence-Based Classification
by: Rolf Teschke
Published: (2025-02-01)

Mechanisms of transcriptional control of glucose metabolism in hepatocytes
by: Konstantin Y. Kulebyakin, et al.
Published: (2016-07-01)

TRANSPLANTATION OF HEPATOCYTES AS THE METHOD OF TREATMENT OF LIVER FAILURE: EXPERIMENTAL AND CLINICAL EXPERIENCE
by: M. Y. Shagidulin, et al.
Published: (2010-06-01)

Efficacy and safety of azvudine versus nirmatrelvir/ritonavir in cancer patients with COVID-19
by: Bohan Jia, et al.
Published: (2025-03-01)

Composite outcome of oral azvudine vs. nirmatrelvir-ritonavir in COVID-19 patients: a retrospective cohort study
by: Jingxia Chen, et al.
Published: (2025-04-01)

Concomitant and sequential administration of nirmatrelvir‐ritonavir and azvudine in patients with COVID‐19 caused by the Omicron variant: Safety and efficacy
by: Guang‐Bin Chen, et al.
Published: (2024-06-01)

Effectiveness of nirmatrelvir/ritonavir and molnupiravir on post-COVID-19 outcomes among outpatients: a target trial emulation investigation
by: Yuchen Wei, et al.
Published: (2025-12-01)